[작성자:] 광준 최
-
3billion’s H1 2026 Revenue Rises 56% to KRW 7.2 Billion
SEOUL, South Korea, August 13, 2026 — 3billion, an AI-powered rare disease diagnostics company, reported consolidated revenue of KRW 7.2 billion for the first half of 2026, up 56% from approximately KRW 4.6 billion in the same period last year. Second-quarter revenue reached KRW 3.8 billion, up 46% year over year and 13% quarter over…
-
Four 3billion Papers Accepted to ICML 2026 Workshops
SEOUL, South Korea, June 30, 2026 — 3billion announced that four of its papers have been accepted for presentation at workshops of the International Conference on Machine Learning (ICML 2026). The conference will take place at COEX in Seoul from July 6 to 11. Alongside NeurIPS and ICLR, ICML is widely regarded as one of…
-
3billion Reports Genetic Screening Results for Patients with Inherited Neuromuscular Disorders
SEOUL, South Korea, July 28, 2026 — 3billion announced that its EASY NMD genetic screening program has helped identify a range of rare genetic disorders in patients with suspected inherited neuromuscular disorders (NMDs), including spinal muscular atrophy (SMA), amyotrophic lateral sclerosis (ALS), and Duchenne and Becker muscular dystrophy (DMD/BMD). EASY NMD (EArly Screening to IdentifY…
-
쓰리빌리언, 상반기 매출 72억원…전년 대비 56% 성장
AI 기반 희귀질환 진단 기업 쓰리빌리언(대표 금창원)은 2026년 상반기 연결 기준 매출액이 72억원으로 전년 동기(약 46억원) 대비 56% 증가했다고 13일 밝혔다. 2분기 매출은 38억원으로 전년 동기 대비 46%, 직전 분기보다 13% 증가했다. 상반기 해외 매출은 약 49억원으로 전년 동기 대비 59% 늘었으며, 전체 매출의 약 69%를 차지했다. 특히 WES·WGS 기반 희귀질환 진단 수요가 꾸준히 이어진…